Stay updated on Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    Change Detected
    Summary
    Revision: v3.3.2 is now shown, replacing the previous v3.3.1. No other study content or functionality appears to be affected.
    Difference
    0.1%
    Check dated 2025-12-01T17:46:49.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Minor wording updates to the Publications section indicate that items are automatically filled from PubMed, and revision numbers have been updated to v3.3.1 and v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-24T14:47:55.000Z thumbnail image
  4. Check
    29 days ago
    Change Detected
    Summary
    Removed the banner that informed users about a lapse in government funding and NIH operating status. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2025-11-17T06:55:30.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    Enrollment updated to 90 participants with a Primary Completion date of 2018-10-11 and a Study Completion date of 2023-09-05.
    Difference
    0.5%
    Check dated 2025-11-03T01:19:15.000Z thumbnail image
  6. Check
    71 days ago
    Change Detected
    Summary
    Major update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.
    Difference
    2%
    Check dated 2025-10-05T10:04:40.000Z thumbnail image
  7. Check
    79 days ago
    Change Detected
    Summary
    Updated the page revision from v3.0.2 to v3.1.0.
    Difference
    0.1%
    Check dated 2025-09-28T03:11:43.000Z thumbnail image

Stay in the know with updates to Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Eribulin/Pembrolizumab in HR+ Metastatic Breast Cancer Clinical Trial page.